company background image
PSTV

Plus Therapeutics NasdaqCM:PSTV Stock Report

Last Price

US$0.50

Market Cap

US$11.1m

7D

-10.3%

1Y

-82.1%

Updated

26 Jun, 2022

Data

Company Financials +
PSTV fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

PSTV Stock Overview

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases.

Plus Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Plus Therapeutics
Historical stock prices
Current Share PriceUS$0.50
52 Week HighUS$2.80
52 Week LowUS$0.41
Beta0.42
1 Month Change-12.72%
3 Month Change-50.28%
1 Year Change-82.06%
3 Year Change-95.86%
5 Year Change-99.91%
Change since IPO-100.00%

Recent News & Updates

Shareholder Returns

PSTVUS BiotechsUS Market
7D-10.3%10.3%6.6%
1Y-82.1%-24.3%-18.4%

Return vs Industry: PSTV underperformed the US Biotechs industry which returned -24.3% over the past year.

Return vs Market: PSTV underperformed the US Market which returned -18.4% over the past year.

Price Volatility

Is PSTV's price volatile compared to industry and market?
PSTV volatility
PSTV Average Weekly Movement13.0%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: PSTV is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: PSTV's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199614Marc Hedrickhttps://www.plustherapeutics.com

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx’s glioblastoma treatment.

Plus Therapeutics Fundamentals Summary

How do Plus Therapeutics's earnings and revenue compare to its market cap?
PSTV fundamental statistics
Market CapUS$11.15m
Earnings (TTM)-US$14.79m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PSTV income statement (TTM)
RevenueUS$0
Cost of RevenueUS$5.98m
Gross Profit-US$5.98m
Other ExpensesUS$8.81m
Earnings-US$14.79m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.67
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio43.2%

How did PSTV perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is PSTV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PSTV?

Other financial metrics that can be useful for relative valuation.

PSTV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does PSTV's PB Ratio compare to its peers?

PSTV PB Ratio vs Peers
The above table shows the PB ratio for PSTV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.5x
ONVO Organovo Holdings
0.5xn/aUS$15.4m
ALLR Allarity Therapeutics
1.1x14.6%US$16.6m
BBI Brickell Biotech
0.9x16.5%US$14.8m
IPIX Innovation Pharmaceuticals
3.3xn/aUS$19.0m
PSTV Plus Therapeutics
0.8x-19.7%US$11.1m

Price-To-Book vs Peers: PSTV is good value based on its Price-To-Book Ratio (0.8x) compared to the peer average (1.5x).


Price to Earnings Ratio vs Industry

How does PSTV's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: PSTV is good value based on its Price-To-Book Ratio (0.8x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is PSTV's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PSTV PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate PSTV's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of PSTV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PSTV's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PSTV's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PSTV's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Plus Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-19.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PSTV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PSTV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PSTV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PSTV is forecast to have no revenue next year.

High Growth Revenue: PSTV is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PSTV's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Plus Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


24.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PSTV is currently unprofitable.

Growing Profit Margin: PSTV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PSTV is unprofitable, but has reduced losses over the past 5 years at a rate of 24.4% per year.

Accelerating Growth: Unable to compare PSTV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PSTV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: PSTV has a negative Return on Equity (-101.04%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Plus Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: PSTV's short term assets ($22.1M) exceed its short term liabilities ($4.9M).

Long Term Liabilities: PSTV's short term assets ($22.1M) exceed its long term liabilities ($5.0M).


Debt to Equity History and Analysis

Debt Level: PSTV has more cash than its total debt.

Reducing Debt: PSTV's debt to equity ratio has reduced from 217% to 43.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PSTV has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PSTV has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 18.7% each year.


Discover healthy companies

Dividend

What is Plus Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PSTV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PSTV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PSTV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PSTV's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PSTV has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Marc Hedrick (58 yo)

18.08yrs

Tenure

US$1,667,279

Compensation

Dr. Marc H. Hedrick, M.D. has been the President of Plus Therapeutics, Inc. (also known as Cytori Therapeutics, Inc.) since May 2004 and has been its Chief Executive Officer since April 2, 2014. Dr. Hedric...


CEO Compensation Analysis

Compensation vs Market: Marc's total compensation ($USD1.67M) is above average for companies of similar size in the US market ($USD749.40K).

Compensation vs Earnings: Marc's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PSTV's management team is considered experienced (2.6 years average tenure).


Board Members

Experienced Board: PSTV's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PSTV insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 118%.


Top Shareholders

Company Information

Plus Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Plus Therapeutics, Inc.
  • Ticker: PSTV
  • Exchange: NasdaqCM
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$11.148m
  • Shares outstanding: 22.20m
  • Website: https://www.plustherapeutics.com

Number of Employees


Location

  • Plus Therapeutics, Inc.
  • 4200 Marathon Boulevard
  • Suite 200
  • Austin
  • Texas
  • 78756
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.